ARS Pharmaceuticals, Inc Cash Flow Quality Index
ARS Pharmaceuticals, Inc cash flow quality index. ARS Pharmaceuticals, Inc (SPRY) has a Cash Flow Quality Index of 0.84x as of December 2024. Operating cash flow of $42.00 Million is below net income of $49.93 Million, suggesting accrual-heavy earnings not yet converted to cash. See SPRY free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of ARS Pharmaceuticals, Inc (2024–2024)
Cash flow quality index of ARS Pharmaceuticals, Inc from 2024 to 2024. Historical Cash Flow Quality Index for ARS Pharmaceuticals, Inc across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore SPRY operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
ARS Pharmaceuticals, Inc Cash Flow Quality Index by Year (2024–2024)
ARS Pharmaceuticals, Inc cash flow quality index by year from 2024 to 2024. Year-by-year earnings quality comparison for ARS Pharmaceuticals, Inc. For the full cash flow conversion analysis, see ARS Pharmaceuticals, Inc cash conversion from operations.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.69x | $13.55 Million | $8.00 Million | — |